Lamassu BioTech is a Cleveland, Ohio-based biopharmaceutical company focused on accelerating the development of transformative treatments for both humans and animals.

We leverage a patient-centric approach, combining innovative processes with strategic partnerships to expedite drug development and bring life-saving therapies to market faster.

Lamassu Biotech’s core expertise lies in genetically targeted therapies, exemplified by SA53, a novel treatment for locally advanced metastatic p53 wild-type tumors, currently in Phase 1/2a clinical trials at Cleveland Clinic, and RABI-767, a small molecule therapy for acute pancreatitis, undergoing Phase II clinical trials in partnership with Arrivo BioVentures.

Our commitment to collaboration with leading institutions like Mayo Clinic and The Ohio State University, coupled with a robust intellectual property portfolio, positions us at the forefront of medical innovation. Accelerating Hope and Healing

SA53 | Lamassu BioTech

Product description

Lamassu BioTech Cleveland, United States (US)

Price: N/A

Lamassu BioTech
Cleveland, United States (US)